Search
capmatinib (Tabrecta)
Indications:
- adults with metastatic non-small cell lung cancer (NSCLC) with c-MET gene exon 14 skipping
Dosage:
- 400mg PO BID ith or without food
Tabs: 150 & 200 mg
Adverse effects:
- most common (> 20%)
- peripheral edema, nausea/vomiting, fatigue, dyspnea, decreased appetite
- photosensitivity
- serious: interstitial lung disease/pneumonitis, hepatotoxicity
Drug interactions:
- avoid strong & moderate CYP3A inducers
Mechanism of action:
- tyrosine kinase inhibitor targeting c-met protein
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Highlights of prescribing information
TABRECTA (capmatinib)tablets, for oral use
https://www.novartis.us/sites/www.novartis.us/files/tabrecta.pdf